4.5 Review

Severe Asthma in Children

出版社

ELSEVIER
DOI: 10.1016/j.jaip.2017.04.031

关键词

Childhood severe asthma; Difficult to treat asthma; Severe asthma phenotypes; Severe asthma treatment; Review

资金

  1. National Institutes of Health
  2. Aerocrine
  3. GlaxoSmithKline
  4. Genentech/Novartis
  5. Teva
  6. Boehringer Ingelheim
  7. scientific advisory board for Merck
  8. Cephalon
  9. DBV Technologies data safety monitoring board
  10. AstraZeneca
  11. American Board of Pediatrics/Pediatric Pulmonary Subboard
  12. Budesonide Research Advisory Board for Teva
  13. advisory board GlaxoSmithKline
  14. advisory board Regeneron
  15. advisory board Merck
  16. advisory board Sanofi
  17. advisory board Novartis
  18. advisory board Aviragen

向作者/读者索取更多资源

Severe asthma in children is associated with significant morbidity and is a highly heterogeneous disorder with multiple clinical phenotypes. Cluster analyses have been performed in several groups to explain some of the heterogeneity of pediatric severe asthma, which is reviewed in this article. The evaluation of a child with severe asthma includes a detailed diagnostic assessment and excluding other possible diagnoses and addressing poor control due to comorbidities, lack of adherence to asthma controller medications, poor technique, and other psychological and environmental factors. Children with severe asthma require significant resources including regular follow-up appointments with asthma education, written asthma action plan, and care by a multidisciplinary team. Management of pediatric severe asthma now includes emerging phenotypic-directed therapies; however, continued research is still needed to further study the long-term outcomes of pediatric severe asthma and its treatment. (C) 2017 American Academy of Allergy, Asthma & Immunology

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据